胸痛方案不一致出院与高敏肌钙蛋白轻度升高患者结局的关联
这项回顾性队列研究纳入2017年1月至2019年9月在某大型多站点健康系统急诊科因胸痛就诊、按高敏肌钙蛋白T加速诊断方案评估、峰值hsTnT在定量下限至52 ng/L之间并出院的10342例患者,比较方案一致与不一致出院者的30天主要不良心血管事件(MACE)。出院患者中29例(0.28%)发生MACE;MACE患者中方案不一致出院比例更高(55.2% vs 11.1%,P<.001),多因素logistic回归仅方案不一致与MACE独立相关(OR 6.42,95%CI 2.94–14.0,P<.001)。峰值hsTnT<12 ng/L时两组MACE无差异;12–51 ng/L时不一致出院者MACE更多(2.30% vs 0.48%,P<.002)。HEART评分≥4分回顾性识别了81.3%的不一致出院MACE患者。
要点
- 峰值hsTnT 12–51 ng/L且方案不一致出院者30天MACE发生率2.30%(14/609),显著高于方案一致出院者的0.48%(5/1047),P<.002。
- 峰值hsTnT<12 ng/L时,方案一致与不一致出院者MACE无差异。
- 多因素logistic回归显示方案不一致出院是MACE的独立相关因素(OR 6.42,95%CI 2.94–14.0,P<.001)。
- HEART评分≥4分回顾性识别了81.3%(13/16)方案不一致出院且发生MACE的患者。
- 出院患者总体30天MACE发生率为0.28%(29/10342)。
适用人群与场景
- 2017年1月至2019年9月在某大型多站点健康系统急诊科因胸痛就诊、按高敏肌钙蛋白T加速诊断方案评估、峰值hsTnT在定量下限至52 ng/L之间、出院并在电子病历中有随访的患者。
诊断标准与关键阈值
- 加速诊断方案(ADP)基于高敏肌钙蛋白T(hsTnT)系列检测。
- 峰值hsTnT分层界值:<12 ng/L;12–51 ng/L;上限52 ng/L。
- HEART评分(病史、心电图、年龄、危险因素、肌钙蛋白)≥4分。
红旗征与不能漏的情况
- 峰值hsTnT 12–51 ng/L且ADP结果不一致(方案不一致出院)时30天MACE风险显著升高(2.30% vs 0.48%,P<.002)。
- 方案不一致出院且HEART评分≥4分:回顾性识别81.3%(13/16)发生MACE的不一致出院患者。
研究设计与关键结果
- 研究类型:回顾性队列研究;样本量10342例;人群为急诊胸痛按hsTnT ADP评估后出院患者;平均(SD)年龄51(17)岁,女性5902例(57%)。
- 30天MACE(心肌梗死、紧急冠状动脉血运重建、全因死亡)共29例(0.28%)。
- MACE患者较无MACE者年龄更大(中位[IQR] 66[53–75]岁 vs 50[38–62]岁;P<.001),既往冠心病比例更高(12[41.4%] vs 1805[17.5%];P=.002),高脂血症比例更高(13[44.8%] vs 2248[21.8%];P=.006)。
- MACE患者中方案不一致出院比例更高(16[55.2%] vs 1145[11.1%];P<.001)。
- 多因素logistic回归仅方案不一致出院与MACE独立相关(OR 6.42,95%CI 2.94–14.0;P<.001)。
- 按峰值hsTnT分层:<12 ng/L时方案一致与不一致出院者MACE无差异;12–51 ng/L时不一致出院者MACE显著更高(14/609[2.30%] vs 5/1047[0.48%];P<.002)。
- HEART评分≥4分回顾性识别了81.3%(13/16)方案不一致出院且发生MACE的患者。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 基于ADP一致“排除”出院的患者30天MACE风险低(总体0.28%),支持该出院路径。
- 峰值hsTnT 12–51 ng/L且ADP不一致出院者30天MACE风险显著升高(2.30% vs 0.48%),提示需重新评估出院决策。
- 作者认为,HEART评分≥4分可能有助于辅助ADP不一致肌钙蛋白系列患者的出院决策。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Accelerated diagnostic protocols (ADPs) for chest pain using high-sensitivity troponin (hsTn) levels have excellent sensitivity and negative predictive value for rapid risk stratification of patients with chest pain. However, little is known about the outcomes of patients who are discharged despite abnormal ADP results, ie, after "ruling-in" with a modest elevation of hsTn.
OBJECTIVE: To determine outcomes of patients discharged following ADP, including those who were ruled in with modestly elevated levels of hsTnT but discharged nonetheless.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients with chest pain who presented to the emergency departments (EDs) of a large multisite health system ED between January 2017 to September 2019. Patients were assessed using an ADP, had a peak hsTnT level measured between the limit of quantitation and 52 ng/L, were discharged, and had follow-up in the electronic medical record. Data analysis was conducted from January 2017 to September 2019.
EXPOSURES: Application of an hsTnT ADP.
MAIN OUTCOMES AND MEASURES: Thirty-day major adverse cardiac events (MACE), including myocardial infarction, urgent coronary revascularization, and all-cause death, comparing patients who were discharged following ADP-concordant vs ADP-discordant results.
RESULTS: Of 10 342 patients with chest pain (mean [SD] age 51 [17] years; 5902 [57%] women) discharged following ADP, 29 (0.28%) had MACE. Patients with MACE were older (median [IQR] age, 66 [53-75] years vs 50 [38-62] years; P < .001) and more likely to have prior CAD (12 [41.4%] vs 1805 [17.5%]; P = .002) and hyperlipidemia (13 [44.8%] vs 2248 [21.8%]; P = .006). Additionally, patients with MACE were 5-fold more likely to have been discharged despite ADP discordance (16 [55.2%] vs 1145 [11.1%]; P < .001). A multivariable logistic regression analysis revealed only ADP discordance was independently associated with MACE (odds ratio, 6.42 [95% CI, 2.94-14.0]; P < .001). When stratified by peak hsTnT level, there were no differences in MACE between ADP-concordant and -discordant discharges provided the peak hsTnT measured was less than 12 ng/L. In contrast, patients with peak hsTnT level between 12 and 51 ng/L were significantly more likely to have MACE if they were discharged after ADP-discordant vs -concordant hsTnT series (14 of 609 [2.30%] vs 5 of 1047 [0.48%]; P < .002). Notably, a HEART (history, electrocardiogram, age, risk factors, troponin) score of 4 or greater retrospectively identified the most ADP-discordant discharges (13 of 16 [81.3%]) who had MACE.
CONCLUSIONS AND RELEVANCE: In this cohort study, an hsTnT ADP identified patients who could be discharged from the ED with low 30-day risk of MACE, provided the discharge was based on ADP-concordant "rule-out." Conversely, the rate of MACE was significantly higher among patients discharged despite ADP discordance. Most patients with ADP-discordant discharges who experienced MACE had a HEART score of 4 or greater, suggesting that application of this score may augment discharge decisions of patients despite ADP-discordant troponin series.
参考来源
- Khan A, Saleem MS, Willner KD, et al. Association of Chest Pain Protocol-Discordant Discharge With Outcomes Among Emergency Department Patients With Modest Elevations of High-Sensitivity Troponin. JAMA Netw Open. 2022. PMID: 35969395. doi:10.1001/jamanetworkopen.2022.26809
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。